This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
Sean Boss
The Market Online, Australia
3 days ago